PMC:7172841 / 25816-26460 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T177","span":{"begin":130,"end":134},"obj":"Body_part"},{"id":"T178","span":{"begin":153,"end":161},"obj":"Body_part"},{"id":"T179","span":{"begin":208,"end":217},"obj":"Body_part"},{"id":"T180","span":{"begin":253,"end":257},"obj":"Body_part"},{"id":"T181","span":{"begin":336,"end":339},"obj":"Body_part"}],"attributes":[{"id":"A177","pred":"fma_id","subj":"T177","obj":"http://purl.org/sig/ont/fma/fma9712"},{"id":"A178","pred":"fma_id","subj":"T178","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A179","pred":"fma_id","subj":"T179","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A180","pred":"fma_id","subj":"T180","obj":"http://purl.org/sig/ont/fma/fma9712"},{"id":"A181","pred":"fma_id","subj":"T181","obj":"http://purl.org/sig/ont/fma/fma84795"}],"text":"In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T19","span":{"begin":130,"end":134},"obj":"Body_part"},{"id":"T20","span":{"begin":253,"end":257},"obj":"Body_part"}],"attributes":[{"id":"A19","pred":"uberon_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/UBERON_0002398"},{"id":"A20","pred":"uberon_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/UBERON_0002398"}],"text":"In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T226","span":{"begin":93,"end":101},"obj":"Disease"},{"id":"T227","span":{"begin":93,"end":97},"obj":"Disease"}],"attributes":[{"id":"A226","pred":"mondo_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A227","pred":"mondo_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T236","span":{"begin":29,"end":30},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T161","span":{"begin":230,"end":232},"obj":"Chemical"},{"id":"T163","span":{"begin":310,"end":312},"obj":"Chemical"},{"id":"T165","span":{"begin":340,"end":342},"obj":"Chemical"}],"attributes":[{"id":"A161","pred":"chebi_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A162","pred":"chebi_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A163","pred":"chebi_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A164","pred":"chebi_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A165","pred":"chebi_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"}],"text":"In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T31","span":{"begin":153,"end":172},"obj":"http://purl.obolibrary.org/obo/GO_0001816"},{"id":"T32","span":{"begin":598,"end":625},"obj":"http://purl.obolibrary.org/obo/GO_0050728"}],"text":"In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T186","span":{"begin":0,"end":354},"obj":"Sentence"},{"id":"T187","span":{"begin":355,"end":644},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T92","span":{"begin":51,"end":71},"obj":"Phenotype"}],"attributes":[{"id":"A92","pred":"hp_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/HP_0002958"}],"text":"In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T815","span":{"begin":51,"end":57},"obj":"UBERON:0002405;GO:0006955"},{"id":"T816","span":{"begin":58,"end":71},"obj":"GO:0006955"},{"id":"T817","span":{"begin":93,"end":103},"obj":"SP_7"},{"id":"T818","span":{"begin":230,"end":234},"obj":"PR:000001393"},{"id":"T819","span":{"begin":310,"end":314},"obj":"PR:000001393"},{"id":"T820","span":{"begin":336,"end":339},"obj":"PR:000029150"},{"id":"T821","span":{"begin":343,"end":353},"obj":"GO:0010467"},{"id":"T822","span":{"begin":449,"end":458},"obj":"DG_39"},{"id":"T823","span":{"begin":476,"end":487},"obj":"DG_35"},{"id":"T50203","span":{"begin":39,"end":47},"obj":"SP_7"},{"id":"T29702","span":{"begin":148,"end":153},"obj":"UBERON:0002405;GO:0006955"},{"id":"T17561","span":{"begin":154,"end":167},"obj":"GO:0006955"},{"id":"T90888","span":{"begin":189,"end":199},"obj":"SP_7"},{"id":"T69958","span":{"begin":326,"end":330},"obj":"PR:000001393"},{"id":"T56935","span":{"begin":406,"end":410},"obj":"PR:000001393"},{"id":"T72906","span":{"begin":432,"end":435},"obj":"PR:000029150"},{"id":"T21106","span":{"begin":439,"end":449},"obj":"GO:0010467"},{"id":"T43307","span":{"begin":546,"end":555},"obj":"DG_39"},{"id":"T89983","span":{"begin":573,"end":584},"obj":"DG_35"}],"text":"In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1012","span":{"begin":230,"end":234},"obj":"Gene"},{"id":"1013","span":{"begin":310,"end":314},"obj":"Gene"},{"id":"1014","span":{"begin":79,"end":87},"obj":"Species"},{"id":"1015","span":{"begin":93,"end":103},"obj":"Species"},{"id":"1016","span":{"begin":635,"end":643},"obj":"Species"},{"id":"1017","span":{"begin":449,"end":458},"obj":"Chemical"},{"id":"1018","span":{"begin":460,"end":470},"obj":"Chemical"},{"id":"1019","span":{"begin":476,"end":487},"obj":"Chemical"}],"attributes":[{"id":"A1012","pred":"tao:has_database_id","subj":"1012","obj":"Gene:3569"},{"id":"A1013","pred":"tao:has_database_id","subj":"1013","obj":"Gene:3569"},{"id":"A1014","pred":"tao:has_database_id","subj":"1014","obj":"Tax:9606"},{"id":"A1015","pred":"tao:has_database_id","subj":"1015","obj":"Tax:2697049"},{"id":"A1016","pred":"tao:has_database_id","subj":"1016","obj":"Tax:9606"},{"id":"A1017","pred":"tao:has_database_id","subj":"1017","obj":"MESH:C000592401"},{"id":"A1018","pred":"tao:has_database_id","subj":"1018","obj":"MESH:C504234"},{"id":"A1019","pred":"tao:has_database_id","subj":"1019","obj":"MESH:C502936"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients."}